The half-life of evantuzumab

Amivantumab (amivantamab-vmjw) can be used as a single agent alone in adults with EGFR-positive non-small cell lung cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) and has not responded to platinum-based treatments. It is also used in combination with the chemotherapy drugs (carboplatin and pemetrexed) as a first-line (initial) treatment for adults with EGFR-positive non-small cell lung cancer that cannot be removed with surgery or has spread to other parts of the body (metastatic).

Evantumumab is considered a monoclonal antibody, which is a laboratory-made immune system protein. It targets two proteins that promote cancer cell growth: EGFR and MET, and is considered a "bispecific" antibody. In its pharmacokinetics, data from in vivo trials show a proportional increase in evantumumab exposure at doses 350 to 1750 mg. Steady state was reached by the ninth infusion. The concentration of evantumumab increased rapidly during cycle 1 and a steady state was observed in cycle 4, with a half-life of 11.3±4.53 days and a mean volume of distribution of 5.13 liters.

Dosage recommendations are based on target saturation calculated using baseline body weight. For patients with a baseline body weight <80 kg, the recommended dose of evantumumab is 1050 mg. For patients weighing more than 80 kg at baseline, the recommended dose is 1400 mg. Evantumumab was administered intravenously weekly for the first five weeks, then every two weeks until disease progression or toxicity occurred. There were no clinically meaningful differences in evantumumab exposure with respect to age, sex, race, creatinine clearance, or hepatic impairment.